

Robert H Dworkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6924192/publications.pdf>

Version: 2024-02-01

97
papers

18,055
citations

94433

37
h-index

43889

91
g-index

99
all docs

99
docs citations

99
times ranked

16598
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural imaging studies of patients with chronic pain: an anatomical likelihood estimate meta-analysis. <i>Pain</i> , 2023, 164, e10-e24.	4.2	8
2	Pragmatic trials of pain therapies: a systematic review of methods. <i>Pain</i> , 2022, 163, 21-46.	4.2	20
3	Partnering with patients in clinical trials of pain treatments: a narrative review. <i>Pain</i> , 2022, 163, 1862-1873.	4.2	6
4	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. <i>Journal of Rheumatology</i> , 2022, 49, 615-621.	2.0	8
5	A comparison of registered and published primary outcomes in clinical trials of opioid use disorder: ACTION review and recommendations. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109447.	3.2	0
6	Diagnostic criteria for idiopathic small fiber neuropathy: A systematic review. <i>Muscle and Nerve</i> , 2021, 63, 170-177.	2.2	22
7	Brain Responses to Noxious Stimuli in Patients With Chronic Pain. <i>JAMA Network Open</i> , 2021, 4, e2032236.	5.9	12
8	AAAPT Diagnostic Criteria for Acute Neuropathic Pain. <i>Pain Medicine</i> , 2021, 22, 616-636.	1.9	11
9	The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTION systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 166-174.	3.4	81
10	Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. <i>Pain</i> , 2021, 162, 2578-2589.	4.2	28
11	Design of Clinical Trials Evaluating Sedation in Critically Ill Adults Undergoing Mechanical Ventilation: Recommendations From Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research (SCEPTER) Recommendation III. <i>Critical Care Medicine</i> , 2021, 49, 1684-1693.	0.9	11
12	Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. <i>Pain</i> , 2021, 162, 2669-2681.	4.2	20
13	Moderate to Severe Chronic Pain in Later Life: Risk and Resilience Factors for Recovery. <i>Journal of Pain</i> , 2021, 22, 1657-1671.	1.4	7
14	The ACTION Guide to Clinical Trials of Pain Treatments, part II: mitigating bias, maximizing value. <i>Pain Reports</i> , 2021, 6, e886.	2.7	7
15	Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 1759-1774.	2.3	3
16	Design and reporting characteristics of clinical trials investigating sedation practices in the paediatric intensive care unit: a scoping review by SCEPTER (Sedation Consortium on Endpoints and) Tj ETQq0 0 0 1gBT /Overlock 10 Tf		
17	Essential statistical principles of clinical trials of pain treatments. <i>Pain Reports</i> , 2021, 6, e863.	2.7	20
18	Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. <i>Supportive Care in Cancer</i> , 2020, 28, 2553-2562.	2.2	33

#	ARTICLE	IF	CITATIONS
19	Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations. <i>Journal of Pain</i> , 2020, 21, 931-942.	1.4	37
20	Idiopathic distal sensory polyneuropathy. <i>Neurology</i> , 2020, 95, 1005-1014.	1.1	49
21	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. <i>Pain</i> , 2020, 161, 2446-2461.	4.2	64
22	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993.	3.2	49
23	Convergent neural representations of experimentally-induced acute pain in healthy volunteers: A large-scale fMRI meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 300-323.	6.1	66
24	Are there really only 2 kinds of people in the world? Evaluating the distribution of change from baseline in pain clinical trials. <i>Pain</i> , 2020, 161, 195-201.	4.2	4
25	Medical Devices to Prevent Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 351.	11.0	4
26	The ACTIONâ€‘APSâ€‘AAPM Pain Taxonomy (AAAPT) Diagnostic Criteria for Acute Pain Conditions: An Introduction. <i>Journal of Pain</i> , 2019, 20, 743-745.	1.4	2
27	Engaging Stakeholders to Promote Safe Anesthesia and Sedation Care in Young Children. <i>Journal of Neurosurgical Anesthesiology</i> , 2019, 31, 125-128.	1.2	4
28	Clinician-rated measures for distal symmetrical axonal polyneuropathy. <i>Neurology</i> , 2019, 93, 346-360.	1.1	19
29	Design and Reporting Characteristics of Clinical Trials of Select Chronic and Recurrent Pediatric Pain Conditions: An Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks Systematic Review. <i>Journal of Pain</i> , 2019, 20, 394-404.	1.4	8
30	AAPT Diagnostic Criteria for Peripheral Neuropathic Pain: Focal and Segmental Disorders. <i>Journal of Pain</i> , 2019, 20, 369-393.	1.4	21
31	A Comparison of the Assay Sensitivity of Average and Worst Pain Intensity in Pharmacologic Trials: An ACTION Systematic Review and Meta-Analysis. <i>Journal of Pain</i> , 2018, 19, 953-960.	1.4	12
32	Age-Related Patterns in Cancer Pain and Its Psychosocial Impact: Investigating the Role of Variability in Physical and Mental Health Quality of Life. <i>Pain Medicine</i> , 2018, 19, 658-676.	1.9	18
33	Efficacy Outcome Measures for Pediatric Procedural Sedation Clinical Trials: An ACTION Systematic Review. <i>Anesthesia and Analgesia</i> , 2018, 126, 956-967.	2.2	14
34	Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 2 Safety: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research Recommendations. <i>Anesthesia and Analgesia</i> , 2018, 127, 1146-1154.	2.2	16
35	Trial designs for chemotherapy-induced peripheral neuropathy prevention. <i>Neurology</i> , 2018, 91, 403-413.	1.1	63
36	The ACTIONâ€‘APSâ€‘AAPM Pain Taxonomy (AAAPT) Multidimensional Approach to Classifying Acute Pain Conditions. <i>Pain Medicine</i> , 2017, 18, 947-958.	1.9	42

#	ARTICLE	IF	CITATIONS
37	The ACTIONâ€‘APSâ€‘AAPM Pain Taxonomy (AAAPT) Multidimensional Approach to Classifying Acute Pain Conditions. <i>Journal of Pain</i> , 2017, 18, 479-489.	1.4	38
38	Chemotherapy-induced peripheral neuropathy clinical trials. <i>Neurology</i> , 2017, 89, 859-869.	1.1	37
39	Phenotypes and treatment response: it's difficult to make predictions, especially about the future. <i>Pain</i> , 2017, 158, 187-189.	4.2	16
40	Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTION Critique and Recommended Considerations. <i>Journal of Pain</i> , 2017, 18, 1287-1294.	1.4	6
41	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. <i>Pain</i> , 2016, 157, 1836-1850.	4.2	152
42	The Role of Psychosocial Processes in the Development and Maintenance of Chronic Pain. <i>Journal of Pain</i> , 2016, 17, T70-T92.	1.4	538
43	Adverse Event Reporting in Clinical Trials of Intravenous and Invasive Pain Treatments: An ACTION Systematic Review. <i>Journal of Pain</i> , 2016, 17, 1137-1149.	1.4	11
44	Participant Preferences for Pharmacologic Chronic Pain Treatment Trial Characteristics: An ACTION Adaptive Choice-Based Conjoint Study. <i>Journal of Pain</i> , 2016, 17, 1198-1206.	1.4	8
45	Approaches to Demonstrating the Reliability and Validity of Core Diagnostic Criteria for Chronic Pain. <i>Journal of Pain</i> , 2016, 17, T118-T131.	1.4	16
46	Comment: Clinical outcome assessments in transition. <i>Neurology</i> , 2016, 87, S10.	1.1	0
47	Measures of outcome for stimulant trials: ACTION recommendations and research agenda. <i>Drug and Alcohol Dependence</i> , 2016, 158, 1-7.	3.2	49
48	Two very different types of clinical importance. <i>Contemporary Clinical Trials</i> , 2016, 46, 11.	1.8	6
49	Deficiencies in reporting of statistical methodology in recent randomized trials of nonpharmacologic pain treatments: ACTION systematic review. <i>Journal of Clinical Epidemiology</i> , 2016, 72, 56-65.	5.0	13
50	Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. <i>Neurology</i> , 2015, 84, 265-272.	1.1	39
51	Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2015, 14, 162-173.	10.2	2,776
52	Validation of the Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Acute Low Back Pain. <i>Journal of Pain</i> , 2015, 16, 357-366.	1.4	97
53	Reporting of Sample Size Calculations in Analgesic Clinical Trials: ACTION Systematic Review. <i>Journal of Pain</i> , 2015, 16, 199-206.e7.	1.4	32
54	Quality of Pain Intensity Assessment Reporting: ACTION Systematic Review and Recommendations. <i>Journal of Pain</i> , 2015, 16, 299-305.	1.4	32

#	ARTICLE	IF	CITATIONS
55	Evaluation of outcome measures for neurogenic claudication. <i>Neurology</i> , 2015, 85, 1250-1256.	1.1	14
56	Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTION Systematic Review. <i>Journal of Pain</i> , 2015, 16, 389-411.	1.4	26
57	Abuse liability—study the intended patient populations. <i>Nature Reviews Neurology</i> , 2015, 11, 182-182.	10.1	0
58	Data Interpretation in Analgesic Clinical Trials With Statistically Nonsignificant Primary Analyses: An ACTION Systematic Review. <i>Journal of Pain</i> , 2015, 16, 3-10.	1.4	42
59	Interpreting patient treatment response in analgesic clinical trials: Implications for genotyping, phenotyping, and personalized pain treatment. <i>Pain</i> , 2014, 155, 457-460.	4.2	33
60	Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTION systematic review. <i>Pain</i> , 2014, 155, 2253-2262.	4.2	23
61	Back to the future: The need to resolve analgesic efficacy in human immunodeficiency virus neuropathy. <i>Pain</i> , 2014, 155, 1913-1915.	4.2	3
62	The ACTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. <i>Journal of Pain</i> , 2014, 15, 241-249.	1.4	159
63	Response to letter to the Editor. <i>Pain</i> , 2014, 155, 1045-1046.	4.2	0
64	Validation of the Short-Form McGill Pain Questionnaire-2 in Younger and Older People With Cancer Pain. <i>Journal of Pain</i> , 2014, 15, 756-770.	1.4	45
65	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 1941-1967.	1.6	976
66	A standard database format for clinical trials of pain treatments: An ACTION—CDISC initiative. <i>Pain</i> , 2013, 154, 11-14.	4.2	5
67	Interventional management of neuropathic pain: NeuPSIG recommendations. <i>Pain</i> , 2013, 154, 2249-2261.	4.2	344
68	Assay sensitivity and study features in neuropathic pain trials. <i>Neurology</i> , 2013, 81, 67-75.	1.1	35
69	Mechanism-based treatment of pain. <i>Pain</i> , 2012, 153, 2300.	4.2	8
70	Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations?. <i>Pain</i> , 2012, 153, 869-875.	4.2	31
71	Treatment Satisfaction in Osteoarthritis and Chronic Low Back Pain: The Role of Pain, Physical and Emotional Functioning, Sleep, and Adverse Events. <i>Journal of Pain</i> , 2011, 12, 416-424.	1.4	45
72	Accelerating the Development of Improved Analgesic Treatments: The ACTION Public—Private Partnership. <i>Pain Medicine</i> , 2011, 12, S109-S117.	1.9	19

#	ARTICLE	IF	CITATIONS
73	Evidence-based clinical trial design for chronic pain pharmacotherapy: A blueprint for ACTION. <i>Pain</i> , 2011, 152, S107-S115.	4.2	75
74	Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. <i>Pain</i> , 2011, 152, 1705-1708.	4.2	36
75	Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. <i>Pain</i> , 2010, 150, 12-16.	4.2	36
76	Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2010, 149, 177-193.	4.2	322
77	Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. <i>Mayo Clinic Proceedings</i> , 2010, 85, S3-S14.	3.0	1,083
78	Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs. <i>Journal of Pain</i> , 2010, 11, 360-368.	1.4	86
79	Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2009, 146, 238-244.	4.2	524
80	A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. <i>Pain</i> , 2009, 142, 209-217.	4.2	75
81	Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). <i>Pain</i> , 2009, 144, 35-42.	4.2	539
82	Health Care Expenditure Burden of Persisting Herpes Zoster Pain. <i>Pain Medicine</i> , 2008, 9, 348-353.	1.9	32
83	Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. <i>Journal of Pain</i> , 2008, 9, 105-121.	1.4	2,564
84	Diagnosis and Assessment of Pain Associated With Herpes Zoster and Postherpetic Neuralgia. <i>Journal of Pain</i> , 2008, 9, 37-44.	1.4	151
85	Randomized Clinical Trials of Pregabalin for Neuropathic Pain: Methods, Results, and Implications. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2008, 3, .	0.0	1
86	Recommendations for the Management of Herpes Zoster. <i>Clinical Infectious Diseases</i> , 2007, 44, S1-S26.	5.8	668
87	Pharmacologic management of neuropathic pain: Evidence-based recommendations. <i>Pain</i> , 2007, 132, 237-251.	4.2	1,740
88	Symptom Profiles Differ in Patients With Neuropathic Versus Non-neuropathic Pain. <i>Journal of Pain</i> , 2007, 8, 118-126.	1.4	108
89	Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2005, 113, 9-19.	4.2	2,915
90	Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. <i>Neurology</i> , 2005, 65, S7-19.	1.1	103

#	ARTICLE	IF	CITATIONS
91	Fibromyalgia from the perspective of neuropathic pain. Journal of rheumatology Supplement, The, 2005, 75, 1-5.	2.2	11
92	Treatment and Prevention of Postherpetic Neuralgia. Clinical Infectious Diseases, 2003, 36, 877-882.	5.8	142
93	An Overview of Neuropathic Pain: Syndromes, Symptoms, Signs, and Several Mechanisms. Clinical Journal of Pain, 2002, 18, 343-349.	1.9	242
94	Acute pain in herpes zoster: the famciclovir database project. Pain, 2001, 94, 113-119.	4.2	60
95	Treatment of Postherpetic Neuralgia. Drugs, 2000, 59, 1113-1126.	10.9	68
96	Famciclovir and Postherpetic Neuralgia. Annals of Internal Medicine, 1999, 131, 712.	3.9	0
97	Randomized Clinical Trials of Pregabalin for Neuropathic Pain: Methods, Results, and Implications. , 0, 167-188.		9